Lexeo Therapeutics (NASDAQ:LXEO) Issues Quarterly Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) posted its earnings results on Monday. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.19), Zacks reports.

Lexeo Therapeutics Stock Up 20.0%

LXEO traded up $0.54 during trading hours on Friday, hitting $3.24. 1,738,822 shares of the company's stock were exchanged, compared to its average volume of 479,671. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $19.50. The firm has a 50 day moving average of $3.07 and a 200 day moving average of $4.97. The firm has a market cap of $107.56 million, a P/E ratio of -1.03 and a beta of 1.27. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01.

Analyst Ratings Changes

LXEO has been the topic of several recent analyst reports. Royal Bank of Canada decreased their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Chardan Capital decreased their target price on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a report on Tuesday. HC Wainwright reduced their price target on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday. Finally, Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $20.20.

Institutional Investors Weigh In On Lexeo Therapeutics

A hedge fund recently raised its stake in Lexeo Therapeutics stock. AQR Capital Management LLC increased its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 370.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,337 shares of the company's stock after buying an additional 39,627 shares during the period. AQR Capital Management LLC owned about 0.15% of Lexeo Therapeutics worth $175,000 at the end of the most recent quarter. Institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.